Linked Life Data

8139604

Source:http://linkedlifedata.com/resource/pubmed/id/8139604

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
1994-4-25
pubmed:abstractText
Three hundred and seventy-six subjects with advanced Parkinson's disease participated in a prospective, double-blind placebo-controlled study of the dopamine agonist pergolide mesylate as an adjunct to Sinemet. At 6 months, patients randomized to pergolide had a statistically significant improvement in total Parkinson's score, scores of activities of daily living, motor function, number of "off" hours, Hoehn and Yahr stage, and numerous parameters of parkinsonian function including bradykinesia, rigidity, gait, and dexterity. This benefit was obtained with the addition of a mean dose of 2.94 mg of pergolide, which permitted a 24.7% reduction in dose of levodopa. Adverse reactions were, for the most part, mild, reversible, and not of major clinical significance. No significant cardiac or electrocardiographic abnormalities were detected. This study demonstrates that pergolide mesylate, as an adjunct to levodopa, is an effective antiparkinsonian agent that provides clinical improvement while permitting a reduction in levodopa dose.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
0885-3185
pubmed:author
pubmed:issnType
Print
pubmed:volume
9
pubmed:owner
NLM
pubmed:authorsComplete
N
pubmed:pagination
40-7
pubmed:dateRevised
2009-10-6
pubmed:meshHeading
pubmed-meshheading:8139604-Activities of Daily Living, pubmed-meshheading:8139604-Adult, pubmed-meshheading:8139604-Aged, pubmed-meshheading:8139604-Antiparkinson Agents, pubmed-meshheading:8139604-Carbidopa, pubmed-meshheading:8139604-Double-Blind Method, pubmed-meshheading:8139604-Drug Combinations, pubmed-meshheading:8139604-Drug Therapy, Combination, pubmed-meshheading:8139604-Electrocardiography, pubmed-meshheading:8139604-Female, pubmed-meshheading:8139604-Humans, pubmed-meshheading:8139604-Levodopa, pubmed-meshheading:8139604-Male, pubmed-meshheading:8139604-Middle Aged, pubmed-meshheading:8139604-Motor Activity, pubmed-meshheading:8139604-Motor Skills, pubmed-meshheading:8139604-Neurologic Examination, pubmed-meshheading:8139604-Parkinson Disease, pubmed-meshheading:8139604-Pergolide
pubmed:year
1994
pubmed:articleTitle
A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease.
pubmed:affiliation
Department of Neurology and Pharmacology, University of South Florida, Tampa.
pubmed:publicationType
Journal Article, Clinical Trial, Research Support, U.S. Gov't, P.H.S., Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Multicenter Study